Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 574 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatosis of Liver Clear all
Recruiting Phase 3 Interventional

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
165
States / cities
Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609
View directory record Official record
Conditions
NAFLD
Interventions
Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Not applicable Interventional

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

NCT02116192
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
11 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Intrahepatic Lipids With Exercise

NCT02181270
View directory record Official record
Conditions
Obese
Interventions
high intensity exercise, continuous moderate exercise
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Not listed Not applicable Interventional

Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).

NCT03848390
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Conventional diet, Modified Time-restricted Feeding, Physical activity, Restricted consumption of sweetened beverages
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT04073368
View directory record Official record
Conditions
NAFLD
Interventions
AXA1957, AXA1125, Placebo
Dietary Supplement
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

NCT00740610
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GS-9450, GS-9450 Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Tucson, Arizona • Fresno, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The University of Michigan Wellness for Liver Health Study

NCT05010070
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
diet and lifestyle program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 13, 2026, 5:24 PM EDT
Not yet recruiting Not applicable Interventional

Isocaloric Navy-Bean Substitution in Adults With MASLD

NCT07730853
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

NCT04812262
View directory record Official record
Conditions
Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions
DD01, Placebo
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Chula Vista, California • Fort Myers, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Orange, California • Poway, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03639623
View directory record Official record
Conditions
Liver Transplant; Complications, NAFLD
Interventions
Saroglitazar
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

NCT03681457
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
LJN452
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

NCT02571192
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, 5.95 μCi RAD
Drug · Radiation
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 13, 2026, 5:24 PM EDT
Completed No phase listed Observational

Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.

NCT03778411
View directory record Official record
Conditions
Advanced Chronic Liver Disease, NASH
Interventions
VCTE with splenic stiffness measurement
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 13, 2026, 5:24 PM EDT
Withdrawn Not applicable Interventional

Reversal of Right Ventricular Steatosis in Pulmonary Hypertension

NCT02966899
View directory record Official record
Conditions
Pulmonary; Hypertension, Steatosis, Right Ventricular Failure
Interventions
Omega-3 fatty acids
Dietary Supplement
Lead sponsor
Wen-Chih Wu
Federal
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 13, 2026, 5:24 PM EDT
Withdrawn Phase 1 Interventional

A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis

NCT03201159
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
VLX103
Drug
Lead sponsor
Gyongyi Szabo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Results available

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

NCT01505673
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Liraglutide, Saline
Drug
Lead sponsor
Ildiko Lingvay
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 13, 2026, 5:24 PM EDT
Active, not recruiting Phase 2 Interventional

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
Interventions
HU6, Placebo
Drug · Other
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Chula Vista, California • Los Angeles, California • Montclair, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 13, 2026, 5:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fully Automated High-Throughput Quantitative MRI of the Liver

NCT05294471
View directory record Official record
Conditions
Healthy, Iron Overload, Liver Fat
Interventions
Non-contrast MRI with novel MRI software
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 13, 2026, 5:24 PM EDT
Completed Not applicable Interventional

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

NCT02663544
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome, Obesity, Diabetes, NAFLD, Inflammation
Interventions
Limited dairy diet, Low-fat dairy diet, Full-fat dairy diet
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 13, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
AZ compound, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 13, 2026, 5:24 PM EDT